Thomas K. Equels, CEO and President of AIM ImmunoTech Inc., filed a Form 4 on November 12, 2026, disclosing an open-market purchase of 39,000 shares of common stock on November 10, 2026.

Key Highlights

  • Reporting person: Thomas K. Equels, identified as Director, CEO and President of AIM ImmunoTech Inc.
  • Transaction: 39,000 shares of common stock acquired (transaction code P) on November 10, 2026.
  • Price paid: $0.138 per share, according to the filing.
  • Post-transaction ownership: Equels directly beneficially owned 293,095 shares of common stock following the reported transaction.
  • No derivative securities were reported as acquired, disposed of, or beneficially owned in Table II of the filing.

Thomas K. Equels Open-Market Purchase of AIM ImmunoTech Common Stock

According to the Form 4 filed with the U.S. Securities and Exchange Commission on November 12, 2026, Thomas K. Equels, who serves as both a Director and as CEO and President of AIM ImmunoTech Inc. (NASDAQ:AIM), reported the acquisition of 39,000 shares of the company's common stock. The transaction was coded "P," indicating an open-market purchase, and took place on November 10, 2026, at a price of $0.138 per share.

Following the reported transaction, the filing states that Equels directly and beneficially owned 293,095 shares of AIM ImmunoTech common stock. The ownership form is listed as direct. No deemed execution date was reported, and no amendment date was indicated, meaning this is an original filing rather than a revision of a prior submission.

The filing contains no entries in Table II covering derivative securities such as options, warrants, or convertible securities. The form was signed by Thomas K. Equels and dated November 12, 2026. No explanatory footnotes or additional responses were included in the Explanation of Responses section of the filing.

What Was Disclosed

The filing disclosed a single open-market purchase of 39,000 shares of AIM ImmunoTech common stock by CEO and President Thomas K. Equels at $0.138 per share on November 10, 2026, bringing his direct beneficial ownership to 293,095 shares.